A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

ABT-089

20 mg ABT-089 taken once-daily for 6 months

Trial Locations (22)

10021

Site Reference ID/Investigator# 16532, New York

27103

Site Reference ID/Investigator# 16519, Winston-Salem

33064

Site Reference ID/Investigator# 16510, Deerfield Beach

33180

Site Reference ID/Investigator# 16515, Miami

33351

Site Reference ID/Investigator# 16541, Sunrise

33407

Site Reference ID/Investigator# 16529, West Palm Beach

33418

Site Reference ID/Investigator# 16545, Palm Beach Gardens

33445

Site Reference ID/Investigator# 16508, Delray Beach

33613

Site Reference ID/Investigator# 16542, Tampa

34601

Site Reference ID/Investigator# 16516, Brooksville

45459

Site Reference ID/Investigator# 16525, Centerville

46260

Site Reference ID/Investigator# 16526, Indianapolis

76309

Site Reference ID/Investigator# 16507, Wichita Falls

85006

Site Reference ID/Investigator# 16543, Phoenix

85351

Site Reference ID/Investigator# 16528, Sun City

90404

Site Reference ID/Investigator# 16521, Santa Monica

92108

Site Reference ID/Investigator# 16520, San Diego

93720

Site Reference ID/Investigator# 16524, Fresno

06518

Site Reference ID/Investigator# 16533, Hamden

07724

Site Reference ID/Investigator# 16527, Eatontown

07450

Site Reference ID/Investigator# 16523, Ridgewood

05201

Site Reference ID/Investigator# 16509, Bennington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY